{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T14:46:21Z","timestamp":1761489981245},"reference-count":27,"publisher":"Elsevier BV","issue":"23","license":[{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,4,18]],"date-time":"2016-04-18T00:00:00Z","timestamp":1460937600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1016\/j.vaccine.2016.04.009","type":"journal-article","created":{"date-parts":[[2016,4,13]],"date-time":"2016-04-13T04:53:53Z","timestamp":1460523233000},"page":"2579-2584","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Pooled-sera hSBA titres predict individual seroprotection in infants and toddlers vaccinated with 4CMenB"],"prefix":"10.1016","volume":"34","author":[{"given":"Sonia","family":"Budroni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annett","family":"Kleinschmidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip","family":"Boucher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Duccio","family":"Medini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2016.04.009_bib0140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-61779-346-2_1","article-title":"Neisseria meningitidis: biology, microbiology, and epidemiology","volume":"799","author":"Rouphael","year":"2012","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.vaccine.2016.04.009_bib0145","unstructured":"European Centre for Disease Prevention and Control. Surveillance of invasive bacterial diseases (2011). 2013."},{"key":"10.1016\/j.vaccine.2016.04.009_bib0150","unstructured":"Centers for Disease Control and Prevention. 2009. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Neisseria meningitidis, 2008. Available via the Internet: http:\/\/www.cdc.gov\/abcs\/reports-findings\/survreports\/mening08.pdf."},{"key":"10.1016\/j.vaccine.2016.04.009_bib0155","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1016\/S0264-410X(00)00554-5","article-title":"Reverse vaccinology, a genome-based approach to vaccine development","volume":"19","author":"Rappuoli","year":"2001","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.04.009_bib0160","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1126\/science.287.5459.1816","article-title":"Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing","volume":"287","author":"Pizza","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2016.04.009_bib0165","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1177\/2051013614557477","article-title":"Prevention of rare diseases: how revolutionary techniques can help vulnerable individuals-the example of serogroup B meningococcal infection","volume":"3","author":"McIntosh","year":"2015","journal-title":"Ther Adv Vaccines"},{"key":"10.1016\/j.vaccine.2016.04.009_bib0170","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1586\/14760584.2013.814862","article-title":"A multicomponent serogroup B meningococcal vaccine is licensed for use in Europe: what do we know, and what are we yet to learn","volume":"12","author":"Martin","year":"2013","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2016.04.009_bib0175","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1517\/14712598.2015.983897","article-title":"The capsular group B meningococcal vaccine, 4CMenB: clinical experience and potential efficacy","volume":"15","author":"Rollier","year":"2015","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.vaccine.2016.04.009_bib0180","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1016\/j.vaccine.2005.01.051","article-title":"Meningococcal surrogates of protection--serum bactericidal antibody activity","volume":"23","author":"Borrow","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.04.009_bib0185","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1084\/jem.129.6.1327","article-title":"Human immunity to the meningococcus II. Development of natural immunity","volume":"129","author":"Goldschneider","year":"1969","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2016.04.009_bib0190","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1086\/522428","article-title":"A framework for assessing immunological correlates of protection in vaccine trials","volume":"196","author":"Qin","year":"2007","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2016.04.009_bib0195","doi-asserted-by":"crossref","first-page":"4494","DOI":"10.1073\/pnas.1019751108","article-title":"Neisseria meningitidis is structured in clades associated with restriction modification systems that modulate homologous recombination","volume":"108","author":"Budroni","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.vaccine.2016.04.009_bib0200","doi-asserted-by":"crossref","first-page":"19490","DOI":"10.1073\/pnas.1013758107","article-title":"Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines","volume":"107","author":"Donnelly","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.vaccine.2016.04.009_bib0205","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1128\/CVI.00202-12","article-title":"Interlaboratory standardization of the sandwich enzyme-linked immunosorbent assay designed for MATS, a rapid, reproducible method for estimating the strain coverage of investigational vaccines","volume":"19","author":"Plikaytis","year":"2012","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2016.04.009_bib0210","doi-asserted-by":"crossref","first-page":"4968","DOI":"10.1016\/j.vaccine.2013.08.006","article-title":"Bactericidal antibody against a representative epidemiological meningococcal serogroup B panel confirms that MATS underestimates 4CMenB vaccine strain coverage","volume":"31","author":"Frosi","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.04.009_bib0215","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/S1473-3099(13)70006-9","article-title":"Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment","volume":"13","author":"Vogel","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2016.04.009_bib0220","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.vaccine.2013.03.063","article-title":"Diversity of Canadian meningococcal serogroup B isolates and estimated coverage by an investigational meningococcal serogroup B vaccine (4CMenB)","volume":"32","author":"Bettinger","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.04.009_bib0225","first-page":"103","article-title":"Predicted strain coverage of a new protein-based meningococcal vaccine in the Czech Republic","volume":"63","author":"Krizova","year":"2014","journal-title":"Epidemiol Mikrobiol Imunol"},{"key":"10.1016\/j.vaccine.2016.04.009_bib0230","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1001\/jama.2012.85","article-title":"Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial","volume":"307","author":"Gossger","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2016.04.009_bib0235","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0140-6736(12)61961-8","article-title":"Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials","volume":"381","author":"Vesikari","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2016.04.009_bib0240","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.ijforecast.2006.03.001","article-title":"Another look at measures of forecast accuracy","volume":"22","author":"Hyndman","year":"2006","journal-title":"Int J Forecasting"},{"key":"10.1016\/j.vaccine.2016.04.009_bib0245","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1016\/j.vaccine.2012.12.022","article-title":"Could the multicomponent meningococcal serogroup B vaccine (4CMenB) control Neisseria meningitidis capsular group X outbreaks in Africa","volume":"31","author":"Hong","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.04.009_bib0250","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1086\/528994","article-title":"Complement-dependent synergistic bactericidal activity of antibodies against factor H-binding protein, a sparsely distributed meningococcal vaccine antigen","volume":"197","author":"Welsch","year":"2008","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2016.04.009_bib0255","doi-asserted-by":"crossref","first-page":"4232","DOI":"10.1128\/IAI.00367-08","article-title":"Fine antigenic specificity and cooperative bactericidal activity of monoclonal antibodies directed at the meningococcal vaccine candidate factor h-binding protein","volume":"76","author":"Beernink","year":"2008","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2016.04.009_bib0260","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1016\/j.vaccine.2010.12.075","article-title":"Cooperative serum bactericidal activity between human antibodies to meningococcal factor H binding protein and neisserial heparin binding antigen","volume":"29","author":"Vu","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.04.009_bib0265","doi-asserted-by":"crossref","first-page":"6503","DOI":"10.1128\/IAI.72.11.6503-6510.2004","article-title":"Development of immunity to serogroup B meningococci during carriage of Neisseria meningitidis in a cohort of university students","volume":"72","author":"Jordens","year":"2004","journal-title":"Infect Immun"},{"issue":"Suppl 2","key":"10.1016\/j.vaccine.2016.04.009_bib0270","doi-asserted-by":"crossref","first-page":"B67","DOI":"10.1016\/j.vaccine.2011.12.126","article-title":"The challenge of post-implementation surveillance for novel meningococcal vaccines","volume":"30","author":"Snape","year":"2012","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16301293?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16301293?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,13]],"date-time":"2018-09-13T11:29:52Z","timestamp":1536838192000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X16301293"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5]]},"references-count":27,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2016,5]]}},"alternative-id":["S0264410X16301293"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.04.009","relation":{},"ISSN":["0264-410X"],"issn-type":[{"type":"print","value":"0264-410X"}],"subject":[],"published":{"date-parts":[[2016,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pooled-sera hSBA titres predict individual seroprotection in infants and toddlers vaccinated with 4CMenB","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.04.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}